No Data
No Data
Xiangyu Medical 2024 Semi-Annual Report
Summary of the 2024 Semi-Annual Report of Xiangyu Healthcare
Xiangyu Medical (688626.SH) released its semi-annual performance with a net income of 56.64 million yuan, a year-on-year decrease of 47.37%.
Xiangyu Medical (688626.SH) disclosed its 2024 interim report, with the company achieving a revenue of 3.38...
Shandong Xiangyu Medical (688626.SH): net income of 56.6359 million yuan in the first half of the year, a year-on-year decrease of 47.37%.
On August 29th, Xiangyu Medical (688626.SH) announced its semi-annual report. During the reporting period, the company achieved a revenue of 337.8593 million yuan, a year-on-year growth of 0.93%; achieved a net income attributable to the owners of the parent company of 56.6359 million yuan, a year-on-year decrease of 47.37%; achieved a net income attributable to the owners of the parent company after deducting non-recurring gains and losses of 53.4371 million yuan, a year-on-year decrease of 43.62%. At the end of the reporting period, the company's total assets were 2,657.0781 million yuan, a year-on-year increase of 2.51%; net assets attributable to shareholders of the listed company were 201 million yuan.
Could The Market Be Wrong About Xiangyu Medical Co.,Ltd (SHSE:688626) Given Its Attractive Financial Prospects?
Xiangyu Medical (688626.SH): Cumulatively repurchased 1.2063% of its shares, the company has completed the share repurchase.
On August 9th, Gelunhui reported that on August 8th, 2024, Xiangyu Medical (688626.SH) completed the share repurchase. The company has actually repurchased 1,930,000 shares, accounting for 1.2063% of the total share capital of the company. The highest repurchase price was 52.19 yuan/share, the lowest repurchase price was 26.80 yuan/share, and the average repurchase price was 41.49 yuan/share. The total amount of funds used was 80,069,563.31 yuan (excluding transaction fees such as transaction commissions and transfer fees).
No Data